GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer  

作　　者：Nuria Rodriguez De Dios Arturo Navarro-Martin Cristina Cigarral Rodolfo Chicas-Sett Rafael Garcia Virginia Garcia Jose Antonio Gonzalez Susana Gonzalo Mauricio Murcia-Mejia Rogelio Robaina Amalia Sotoca Carmen Vallejo German Valtuena Felipe Counago 

机构地区：[1]Department of Radiation Oncology,Hospital del Mar,Barcelona 08003,Spain [2]Radiation Oncology Research Group,Hospital Del Mar Medical Research Institution,Barcelona 08003,Spain [3]Department of Experimental and Health Sciences,Pompeu Fabra University,Barcelona 08003,Spain [4]Department of Radiation Oncology,Thoracic Malignancies Unit,Hospital Duran i Reynals.ICO,L´Hospitalet de L,Lobregat 08908,Spain [5]Department of Radiation Oncology,Hospital Clinico de Salamanca,Salamanca 37007,Spain [6]Department of Radiation Oncology,ASCIRES Grupo Biomedico,Valencia 46004,Spain [7]Department of Radiation Oncology,Hospital Ruber Internacional,Madrid 28034,Spain [8]Department of Radiation Oncology,Hospital Universitario Arnau de Vilanova,Lleida 25198,Spain [9]Department of Radiation Oncology,Genesis Care-Spain,Sevilla 41092,Spain [10]Department of Radiation Oncology,Hospital Universitario La Princesa,Madrid 28006,Spain [11]Department of Radiation Oncology,Hospital Universitario Sant Joan de Reus,Reus 43204,Tarragona,Spain [12]Department of Radiation Oncology,Hospital Universitario Ramon y Cajal,Madrid 28034,Spain [13]Department of Radiation Oncology,Hospital Clinico Universitario Lozano Blesa,Zaragoza 50009,Spain [14]Department of Radiation Oncology,Hospital Universitario Quirónsalud,Madrid 28223,Spain [15]Department of Radiation Oncology,Hospital La Luz,Madrid 28003,Spain [16]Department of Clinical,Universidad Europea,Madrid 28670,Spain

出　　处：《World Journal of Clinical Oncology》2022年第4期237-266,共30页世界临床肿瘤学杂志（英文版）

摘　　要：Non-small cell lung cancer(NSCLC) is a heterogeneous disease accounting for approximately 85% of all lung cancers. Only 17% of patients are diagnosed at an early stage. Treatment is multidisciplinary and radiotherapy plays a key role in all stages of the disease. More than 50% of patients with NSCLC are treated with radiotherapy(curative-intent or palliative). Technological advancesincluding highly conformal radiotherapy techniques, new immobilization and respiratory control systems, and precision image verification systems-allow clinicians to individualize treatment to maximize tumor control while minimizing treatment-related toxicity. Novel therapeutic regimens such as moderate hypofractionation and advanced techniques such as stereotactic body radiotherapy(SBRT) have reduced the number of radiotherapy sessions. The integration of SBRT into routine clinical practice has radically altered treatment of early-stage disease. SBRT also plays an increasingly important role in oligometastatic disease. The aim of the present guidelines is to review the role of radiotherapy in the treatment of localized, locally-advanced, and metastatic NSCLC. We review the main radiotherapy techniques and clarify the role of radiotherapy in routine clinical practice. These guidelines are based on the best available evidence. The level and grade of evidence supporting each recommendation is provided.

关 键 词：RADIOTHERAPY Non-small cell lung cancer GUIDELINES Stereotactic radiation therapy Hypofractionated radiation Oligometastasis 

分 类 号：R73[医药卫生—肿瘤]